BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Dupixent Discussions - ECPv6.15.19//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:Dupixent Discussions X-ORIGINAL-URL:https://www.dupixentdiscussions.com X-WR-CALDESC:Events for Dupixent Discussions REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/New_York BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20240310T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20241103T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20250309T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20251102T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20260308T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20261101T060000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:America/Los_Angeles BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20240310T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20241103T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20250309T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20251102T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20260308T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20261101T090000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:America/Chicago BEGIN:DAYLIGHT TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:CDT DTSTART:20240310T080000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:CST DTSTART:20241103T070000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:CDT DTSTART:20250309T080000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:CST DTSTART:20251102T070000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:CDT DTSTART:20260308T080000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:CST DTSTART:20261101T070000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/New_York:20251030T121500 DTEND;TZID=America/New_York:20251030T131500 DTSTAMP:20260408T143229 CREATED:20250829T203315Z LAST-MODIFIED:20250926T005436Z UID:10000735-1761826500-1761830100@www.dupixentdiscussions.com SUMMARY:A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Marc Serota\, MD DESCRIPTION:Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=93096101600″] URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-marc-serota-md/ LOCATION:Virtual (Zoom) CATEGORIES:Multi-Indication (AD/PN/CSU/BP) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Marc-Serota-e1705692168783-K9yvcY.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20251029T121500 DTEND;TZID=America/Los_Angeles:20251029T131500 DTSTAMP:20260408T143229 CREATED:20250829T203314Z LAST-MODIFIED:20250919T211551Z UID:10000734-1761740100-1761743700@www.dupixentdiscussions.com SUMMARY:Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Ben Ehst\, MD DESCRIPTION:Learn more about itch in patients with atopic dermatitis (AD)\, prurigo nodularis (PN)\, and chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=97139430213″] URL:https://www.dupixentdiscussions.com/event/beneath-the-itch-the-role-of-type-2-inflammation-and-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-ben-ehst-md/ LOCATION:Virtual (Zoom) CATEGORIES:Multi-Indication (AD/PN/CSU/BP) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2023/05/Benjamin-Ehst-MD.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20251029T121500 DTEND;TZID=America/New_York:20251029T124500 DTSTAMP:20260408T143229 CREATED:20250829T203314Z LAST-MODIFIED:20250926T005413Z UID:10000733-1761740100-1761741900@www.dupixentdiscussions.com SUMMARY:A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Douglas DiRuggiero\, PA-C DESCRIPTION:This program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. \nRegister \n  URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-douglas-diruggiero-pa-c/ LOCATION:Virtual (Zoom) CATEGORIES:Bullous Pemphigoid (BP) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/05/Douglas-DiRuggiero-PA-C.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20251028T121500 DTEND;TZID=America/New_York:20251028T131500 DTSTAMP:20260408T143229 CREATED:20250829T203312Z LAST-MODIFIED:20250919T211533Z UID:10000732-1761653700-1761657300@www.dupixentdiscussions.com SUMMARY:DUPIXENT®(dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Roopen Patel\, MD DESCRIPTION:Join us for a virtual discussion with an expert speaker and an adult patient with atopic dermatitis (AD) to Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=94221308275″] URL:https://www.dupixentdiscussions.com/event/dupixent%c2%a8-dupilumab-patient-story-followed-by-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-roopen-patel-md/ LOCATION:Virtual (Zoom) CATEGORIES:Atopic Dermatitis (AD) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Roopen-Patel-MD-vKymuR.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Chicago:20251027T121500 DTEND;TZID=America/Chicago:20251027T131500 DTSTAMP:20260408T143229 CREATED:20250829T203312Z LAST-MODIFIED:20260206T162535Z UID:10000731-1761567300-1761570900@www.dupixentdiscussions.com SUMMARY:Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP) by Timothy Patton\, DO DESCRIPTION:Learn more about the diagnosis and assessment of bullous pemphigoid (BP) including clinical manifestations\, key\nlaboratory investigations for diagnostic evaluation\, consensus-based recommendations and a treatment option for appropriate BP patients URL:https://www.dupixentdiscussions.com/event/pearls-and-common-challenges-for-the-diagnosis-of-bullous-pemphigoid-bp-by-timothy-patton-dp/ LOCATION:Virtual (Zoom) CATEGORIES:Bullous Pemphigoid (BP) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/06/Timothy-Patton-DO.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Chicago:20251023T121500 DTEND;TZID=America/Chicago:20251023T131500 DTSTAMP:20260408T143229 CREATED:20250829T203311Z LAST-MODIFIED:20250919T211509Z UID:10000730-1761221700-1761225300@www.dupixentdiscussions.com SUMMARY:Clinical Case Discussion: An Adult Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age by Marshall Shuler\, MD DESCRIPTION:Join us for a program discussing a real-world case of an adult patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=92580673185″] URL:https://www.dupixentdiscussions.com/event/clinical-case-discussion-an-adult-patient-with-uncontrolled-moderate-to-severe-atopic-dermatitis-and-a-treatment-option-for-appropriate-patients-6-months-of-age-by-marshall-shuler-md/ LOCATION:Virtual (Zoom) CATEGORIES:Atopic Dermatitis (AD) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/06/Marshall-Shuler-MD.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20251022T121500 DTEND;TZID=America/Los_Angeles:20251022T131500 DTSTAMP:20260408T143229 CREATED:20250829T203311Z LAST-MODIFIED:20250924T195827Z UID:10000729-1761135300-1761138900@www.dupixentdiscussions.com SUMMARY:DUPIXENT@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Zakiya Rice\, MD DESCRIPTION:Join us for a virtual discussion with an expert speaker and an adult patient with prurigo nodularis (PN) to Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=94142696433″] URL:https://www.dupixentdiscussions.com/event/dupixent%c2%a8-dupilumab-patient-story-followed-by-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-zakiya-rice-md/ LOCATION:Virtual (Zoom) CATEGORIES:Prurigo Nodularis (PN) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Zakiya-Rice-MD-9UKcCE.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20251022T121500 DTEND;TZID=America/New_York:20251022T124500 DTSTAMP:20260408T143229 CREATED:20250829T203318Z LAST-MODIFIED:20250926T005354Z UID:10000739-1761135300-1761137100@www.dupixentdiscussions.com SUMMARY:A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Eileen Cheever\, PA-C DESCRIPTION:This program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. \nRegister \n  URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-eileen-cheever-pa-c/ LOCATION:Virtual (Zoom) CATEGORIES:Atopic Dermatitis (AD) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/06/Eileen-Cheever-PA-C.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Chicago:20251021T121500 DTEND;TZID=America/Chicago:20251021T131500 DTSTAMP:20260408T143229 CREATED:20250829T203310Z LAST-MODIFIED:20250926T004207Z UID:10000728-1761048900-1761052500@www.dupixentdiscussions.com SUMMARY:The Shades of Atopic Dermatitis in Skin of Color and a Treatment Option for Appropriate Patients with Type 2 Inflammation by Fred Ghali\, MD DESCRIPTION:Learn more about the distinctive ways that atopic dermatitis (AD) may present in patients with skin of color and a treatment option that may help appropriate patients with Type 2 inflammation. [gravityform id=”1″ field_values=”zoomid=98568417023″] URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-fred-ghali-md/ LOCATION:Virtual (Zoom) CATEGORIES:Atopic Dermatitis (AD) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Fred-Ghali-MD.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20251021T121500 DTEND;TZID=America/Los_Angeles:20251021T131500 DTSTAMP:20260408T143229 CREATED:20250829T203309Z LAST-MODIFIED:20250919T211401Z UID:10000727-1761048900-1761052500@www.dupixentdiscussions.com SUMMARY:The Many Faces of Type 2 Inflammation: Unraveling Its Role Across Dermatologic Conditions and a Treatment Option for Appropriate Patients. by Linda Stein Gold\, MD DESCRIPTION:Learn more about how Type 2 inflammation contributes to the clinical manifestations of atopic dermatitis (AD)\, prurigo nodularis (PN)\, and chronic spontaneous urticaria (CSU); which cytokines play key roles in driving this activity; and a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=97180233477″] URL:https://www.dupixentdiscussions.com/event/the-many-faces-of-type-2-inflammation-unraveling-its-role-across-dermatologic-conditions-and-a-treatment-option-for-appropriate-patients-by-linda-stein-gold-md/ LOCATION:Virtual (Zoom) CATEGORIES:Multi-Indication (AD/PN/CSU/BP) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Linda-Stein-Gold-MD-rJXGOQ.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Chicago:20251020T121500 DTEND;TZID=America/Chicago:20251020T131500 DTSTAMP:20260408T143229 CREATED:20250829T203309Z LAST-MODIFIED:20250919T211348Z UID:10000726-1760962500-1760966100@www.dupixentdiscussions.com SUMMARY:DUPIXENT® (dupilumab) Pediatric Caregiver Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Dareen Siri\, MD DESCRIPTION:Join us for a virtual discussion with an expert speaker and a caregiver of a pediatric patient with atopic dermatitis (AD) to learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=91691990582″] URL:https://www.dupixentdiscussions.com/event/dupixent%c2%a8-dupilumab-patient-story-followed-by-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-dareen-siri-md/ LOCATION:Virtual (Zoom) CATEGORIES:Atopic Dermatitis (AD) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/04/Dareen-Siri-MD.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Chicago:20251016T121500 DTEND;TZID=America/Chicago:20251016T131500 DTSTAMP:20260408T143229 CREATED:20250829T203308Z LAST-MODIFIED:20250926T004057Z UID:10000725-1760616900-1760620500@www.dupixentdiscussions.com SUMMARY:Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age by Dareen Siri\, MD DESCRIPTION:Join us for a program discussing a real-world case of a pediatric patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation. [gravityform id=”1″ field_values=”zoomid=93788306547″] URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-dareen-siri-md/ LOCATION:Virtual (Zoom) CATEGORIES:Atopic Dermatitis (AD) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/04/Dareen-Siri-MD.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20251016T121500 DTEND;TZID=America/New_York:20251016T131500 DTSTAMP:20260408T143229 CREATED:20250829T203308Z LAST-MODIFIED:20250919T211325Z UID:10000724-1760616900-1760620500@www.dupixentdiscussions.com SUMMARY:Clinical Case Discussion: An Adult Patient with Prurigo Nodularis and a Treatment Option for Appropriate Patients 18+ Years of Age by Michael Payette\, MD DESCRIPTION:Join us for a program discussing a real-world case of an adult patient with prurigo nodularis (PN) and a treatment option that may help appropriate patients.[gravityform id=”1″ field_values=”zoomid=96909945859″] URL:https://www.dupixentdiscussions.com/event/clinical-case-discussion-a-62-year-old-female-with-itchy-skin-lesions-could-it-be-pn-by-michael-payette-md/ LOCATION:Virtual (Zoom) CATEGORIES:Prurigo Nodularis (PN) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/06/Michael-Payette-MD.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20251015T121500 DTEND;TZID=America/Los_Angeles:20251015T131500 DTSTAMP:20260408T143229 CREATED:20250829T203308Z LAST-MODIFIED:20250919T211311Z UID:10000723-1760530500-1760534100@www.dupixentdiscussions.com SUMMARY:Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP) by Matthew Lewis\, MD DESCRIPTION:Learn more about the diagnosis and assessment of bullous pemphigoid (BP) including clinical manifestations\, key\nlaboratory investigations for diagnostic evaluation\, consensus-based recommendations and a treatment option for appropriate BP patients[gravityform id=”1″ field_values=”zoomid=91473816744″] URL:https://www.dupixentdiscussions.com/event/pearls-and-common-challenges-for-the-diagnosis-of-bullous-pemphigoid-bp-by-matthew-lewis-md/ LOCATION:Virtual (Zoom) CATEGORIES:Bullous Pemphigoid (BP) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/06/Matthew-Lewis-MD.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Chicago:20251015T121500 DTEND;TZID=America/Chicago:20251015T131500 DTSTAMP:20260408T143229 CREATED:20250829T203302Z LAST-MODIFIED:20250919T211259Z UID:10000722-1760530500-1760534100@www.dupixentdiscussions.com SUMMARY:Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Ty Hanson\, DO DESCRIPTION:Learn more about itch in patients with atopic dermatitis (AD)\, prurigo nodularis (PN)\, and chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=99633835139″] URL:https://www.dupixentdiscussions.com/event/beneath-the-itch-the-role-of-type-2-inflammation-and-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-ty-hanson-do/ LOCATION:Virtual (Zoom) CATEGORIES:Multi-Indication (AD/PN/CSU/BP) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Ty-Hanson-DO.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20251014T121500 DTEND;TZID=America/New_York:20251014T131500 DTSTAMP:20260408T143229 CREATED:20250829T203302Z LAST-MODIFIED:20250919T211243Z UID:10000721-1760444100-1760447700@www.dupixentdiscussions.com SUMMARY:DUPIXENT@ (dupilumab) Pediatric Caregiver Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Lisa Swanson\, MD DESCRIPTION:Join us for a virtual discussion with an expert speaker and a caregiver of a pediatric patient with atopic dermatitis (AD) to learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=95867877266″] URL:https://www.dupixentdiscussions.com/event/dupixent%c2%a8-dupilumab-pediatric-caregiver-story-followed-by-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-lisa-swanson-md/ LOCATION:Virtual (Zoom) CATEGORIES:Atopic Dermatitis (AD) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Lisa-Swanson-MD-uTtlDn.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Chicago:20251009T121500 DTEND;TZID=America/Chicago:20251009T131500 DTSTAMP:20260408T143229 CREATED:20250829T203302Z LAST-MODIFIED:20250920T005122Z UID:10000720-1760012100-1760015700@www.dupixentdiscussions.com SUMMARY:Exploring the Pathophysiology of Type 2 Inflammation in Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age by Cynthia Trickett\, PA-C DESCRIPTION:Learn more about the evolving understanding of the pathophysiology of chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate CSU patients 12+ years of age. [gravityform id=”1″ field_values=”zoomid=97704866735″] URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-cynthia-trickett-pa-c/ LOCATION:Virtual (Zoom) CATEGORIES:Chronic Spontaneous Urticaria (CSU) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Cynthia-Trickett-PA-C.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20251008T121500 DTEND;TZID=America/New_York:20251008T124500 DTSTAMP:20260408T143229 CREATED:20250829T203301Z LAST-MODIFIED:20250926T005312Z UID:10000719-1759925700-1759927500@www.dupixentdiscussions.com SUMMARY:A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Gina Mangin\, PA-C DESCRIPTION:This program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. \nRegister \n  URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-gina-mangin-pa-c/ LOCATION:Virtual (Zoom) CATEGORIES:Prurigo Nodularis (PN) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/06/Gina-Mangin-PA-C.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20251007T121500 DTEND;TZID=America/Los_Angeles:20251007T131500 DTSTAMP:20260408T143229 CREATED:20250829T203301Z LAST-MODIFIED:20250919T211133Z UID:10000718-1759839300-1759842900@www.dupixentdiscussions.com SUMMARY:The Many Faces of Type 2 Inflammation: Unraveling Its Role Across Dermatologic Conditions and a Treatment Option for Appropriate Patients by Justin Love\, PA-C DESCRIPTION:Learn more about how Type 2 inflammation contributes to the clinical manifestations of atopic dermatitis (AD)\, prurigo nodularis (PN)\, and chronic spontaneous urticaria (CSU); which cytokines play key roles in driving this activity; and a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=97505469030″] URL:https://www.dupixentdiscussions.com/event/the-many-faces-of-type-2-inflammation-unraveling-its-role-across-dermatologic-conditions-and-a-treatment-option-for-appropriate-patients-by-justin-love-pa-c/ LOCATION:Virtual (Zoom) CATEGORIES:Multi-Indication (AD/PN/CSU/BP) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Justin-Love-PA-C.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20251006T121500 DTEND;TZID=America/New_York:20251006T131500 DTSTAMP:20260408T143229 CREATED:20250829T203258Z LAST-MODIFIED:20250920T005047Z UID:10000717-1759752900-1759756500@www.dupixentdiscussions.com SUMMARY:Clinical Case Discussion: An Adult Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age by Andrew Baker\, PA-C DESCRIPTION:Join us for a program discussing a real-world case of an adult patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation. \n[gravityform id=”1″ field_values=”zoomid=96374288045″] URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-andrew-baker-pa-c/ LOCATION:Virtual (Zoom) CATEGORIES:Atopic Dermatitis (AD) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Andrew-Baker-PA-C.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20251002T121500 DTEND;TZID=America/New_York:20251002T131500 DTSTAMP:20260408T143229 CREATED:20250829T203258Z LAST-MODIFIED:20250926T005252Z UID:10000716-1759407300-1759410900@www.dupixentdiscussions.com SUMMARY:A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Justin Greiwe\, MD DESCRIPTION:Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=92185067286″] URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-justin-greiwe-md/ LOCATION:Virtual (Zoom) CATEGORIES:Chronic Spontaneous Urticaria (CSU) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Justin-Greiwe-wdrEP0.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Chicago:20251001T121500 DTEND;TZID=America/Chicago:20251001T131500 DTSTAMP:20260408T143229 CREATED:20250829T203257Z LAST-MODIFIED:20250919T211028Z UID:10000715-1759320900-1759324500@www.dupixentdiscussions.com SUMMARY:Diagnosing and Assessing Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age by Raj Chovatiya\, MD DESCRIPTION:Learn more about the diagnosis and assessment of chronic spontaneous urticaria (CSU)\, including its clinical manifestations\, diagnostic evaluation\, assessment scales\, and a treatment option for appropriate CSU patients 12+ years of age. \n[gravityform id=”1″ field_values=”zoomid=99810660287″] URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-raj-chovatiya-md/ LOCATION:Virtual (Zoom) CATEGORIES:Chronic Spontaneous Urticaria (CSU) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Raj-Chovatiya-1-e1705617016350-65OSWK.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20250930T121500 DTEND;TZID=America/Los_Angeles:20250930T131500 DTSTAMP:20260408T143229 CREATED:20250829T203257Z LAST-MODIFIED:20250926T005136Z UID:10000714-1759234500-1759238100@www.dupixentdiscussions.com SUMMARY:A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Kathryn Sowerwine\, MD DESCRIPTION:Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=98655284668″] URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-kathryn-sowerwine-md/ LOCATION:Virtual (Zoom) CATEGORIES:Chronic Spontaneous Urticaria (CSU) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Kathryn-Sowerwine-e1705692143713-eb2DRh.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20250929T121500 DTEND;TZID=America/New_York:20250929T124500 DTSTAMP:20260408T143229 CREATED:20250829T203257Z LAST-MODIFIED:20250926T005114Z UID:10000713-1759148100-1759149900@www.dupixentdiscussions.com SUMMARY:A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Andrew Mastro\, PA-C DESCRIPTION:This program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. \nRegister \n  URL:https://www.dupixentdiscussions.com/event/exploring-the-pathophysiology-of-type-2-inflammation-in-chronic-spontaneous-urticaria-csu-and-a-treatment-option-for-appropriate-csu-patients-12-years-of-age-by-andrew-mastro-pa-c/ LOCATION:Virtual (Zoom) CATEGORIES:Chronic Spontaneous Urticaria (CSU) ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Andrew-Mastro-PA-C-e1756498706590.png END:VEVENT END:VCALENDAR